From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Some of the best new research developments were highlighted at the Clinical Trials plenary session on April 20 during AAN 2016. In part 1 of this slideshow, we share results of the first four of eight trials featured. Natalia S. Rost, MD, Vice Chair of the Science Committee and Petra Kauffman, MS, member of the Science Committee, led the session.
The Wide-Reaching Impact of Multiple Sclerosis DMT Wastes: Darin T. Okuda, MD; Karin Cook
Pepinemab’s Upregulation of SEMA4D Expression Warrants Further Development in Huntington, Alzheimer Disease
Future Relapse Remission in Multiple Sclerosis Impacted by Retinal Layer Thinning
Using the Cognitive Stress Test to Distinguish Pre-MCI and Amnestic MCI: Leeron Nahmias, BS